Prolactin: The new biology of an old hormone

被引:307
作者
Goffin, V [1 ]
Binart, N [1 ]
Touraine, P [1 ]
Kelly, PA [1 ]
机构
[1] Fac Med Necker Enfants Malad, INSERM, U344, F-75730 Paris 15, France
关键词
prolactin receptor; animal models; extrapituitary; mammary gland; cancer;
D O I
10.1146/annurev.physiol.64.081501.131049
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Prolactin (PRL) is a paradoxical hormone. Historically known as the pituitary hormone of lactation, it has had attributed to it more than 300 separate actions, which can be correlated to the quasi-ubiquitous distribution of its receptor. Meanwhile, PRL-related knockout models have mainly highlighted its irreplaceable role in functions of lactation and reproduction, which suggests that most of its other reported target tissues are presumably modulated by, rather than strictly dependent on, PRL. The multiplicity of PRL actions in animals is in direct opposition to the paucity of arguments that suggest its involvement in human pathophysiology other than effects on reproduction. Although many experimental data argue for a role of PRL in the progression of some tumors, such as breast and prostate cancers, drugs lowering circulating PRL levels are ineffective. This observation opens new avenues for research into the understanding of whether local production of PRL is involved in tumor growth and, if so, how extrapituitary PRL synthesis is regulated. Finally, the physiological relevance of PRL variants, such as the antiangiogenic 16K-like PRL fragments, needs to be elucidated. This review is aimed at critically discussing how these recent findings have renewed the manner in which PRL should be considered as a multifunctional hormone.
引用
收藏
页码:47 / 67
页数:23
相关论文
共 122 条
[1]   Recruitment of the protein-tyrosine phosphatase SHP-2 to the C-terminal tyrosine of the prolactin receptor and to the adaptor protein Gab2 [J].
Ali, S ;
Ali, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39073-39080
[2]   PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation [J].
Ali, S ;
Chen, ZJ ;
Lebrun, JJ ;
Vogel, W ;
Kharitonenkov, A ;
Kelly, PA ;
Ullrich, A .
EMBO JOURNAL, 1996, 15 (01) :135-142
[3]   Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study [J].
Alvarez-Nemegyei, J ;
Cobarrubias-Cobos, A ;
Escalante-Triay, F ;
Sosa-Munoz, J ;
Miranda, JM ;
Jara, LJ .
LUPUS, 1998, 7 (06) :414-419
[4]   SERUM IMMUNOREACTIVE AND BIOACTIVE LACTOGENIC HORMONES IN ADVANCED BREAST-CANCER PATIENTS TREATED WITH BROMOCRIPTINE AND OCTREOTIDE [J].
ANDERSON, E ;
FERGUSON, JE ;
MORTEN, H ;
SHALET, SM ;
ROBINSON, EL ;
HOWELL, A .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) :209-217
[5]   THE RECEPTORS FOR PROLACTIN AND GROWTH-HORMONE ARE LOCALIZED IN THE SAME REGION OF HUMAN CHROMOSOME-5 [J].
ARDEN, KC ;
BOUTIN, JM ;
DJIANE, J ;
KELLY, PA ;
CAVENEE, WK .
CYTOGENETICS AND CELL GENETICS, 1990, 53 (2-3) :161-165
[6]  
Astwood EB, 1938, P SOC EXP BIOL MED, V38, P713
[7]   The regulation of corpus luteum function by hypophysial luteotrophin [J].
Astwood, EB .
ENDOCRINOLOGY, 1941, 28 (02) :309-320
[8]   Involvement of SOCS-1, the suppressor of cytokine signaling, in the prevention of prolactin-responsive gene expression in decidual cells [J].
Barkai, U ;
Prigent-Tessier, A ;
Tessier, C ;
Gibori, GB ;
Gibori, G .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (04) :554-563
[9]  
BARTKE A, 1980, FED PROC, V39, P2577